8549 POSTER

Outcome of surgery and post-operative radiotherapy of major salivary gland carcinoma: a single institute experience

S. Muzumder[1], S. Goyal[1], T. Puri[1], J. Kaur[1], B.K. Mohanti[1], G.K. Rath[1].
[1]*Institute Rotary Cancer Hospital, Radiotherapy, New Delhi, India*

Background: We intended to determine clinic-pathologic features, management & recurrence pattern of major salivary gland carcinoma treated with surgery & post-operative radiotherapy (PORT).
Material and Methods: We retrospectively reviewed 106 cases of major salivary gland tumor seen at our centre (1998−2008). 65 cases were selected for analysis (exclusions: benign, palliative, non-carcinomas). Statistical analysis was performed using SPSS 15.0. Recurrence free survival (RFS) was obtained using Kaplan-Meier method.
Results: Median age was 35 years with male: female ratio of 1.3:1. Tumour location was parotid (56, 86.2%) or submandibular gland (9, 13.8%). Histology was: 28 mucoepidermoid (43%), 10 adenocarcinoma (15.4%), 7 adenoid cystic (10.8%), 4 squamous cell carcinoma (6.2%), 3 salivary duct carcinoma (4.6%) and 13 other (20%). 39 cases (60%) were primary while 26 (40%) were recurrent. Optimal surgery was performed in 59 pts (90.8%). 43 pts (66.2%) underwent neck dissection, of which 14 (32.5%) had nodal metastasis. Surgical margins were: negative 41 (63.1%), positive 11(16.9%), close 4(6.2%) & unknown 9 (13.8%). Tumor size was: <2 cm = 7, 2−4 cm = 17, >4 cm =14 & unknown = 27. Other pathologic findings were: perineural invasion 9 (13.8%), soft tissue infiltration 20 (30.8%), bony involvement 1 (1.5%), skin infiltration 8 (12.3%) and facial nerve involvement 10 (12.3%). Overall, 61 (93.8%) pts complied with the prescribed radiotherapy. Median dose of PORT was 60 Gy. Common radiotherapy techniques used were electron-photon combination (38, 62.3%) and photon wedge pair (18, 29.5%). RT plan was conventional in 36 (59%) and CT-based in 25 (41%). Median interval between surgery & PORT was 48 days (range: 20−210). Median duration of PORT was 45 days and overall treatment time was 93 days. The median follow-up was 13.1 months (range 2−70). Mean RFS was 42.68 months. 12 pts (18.5%) recurred with a median time to recurrence of 16.9 months. Sites of recurrence were local (2), nodal (4) and distal (5). One patient had both local & distal recurrence. The site of metastasis was lung, liver, brain & bone. Salvage therapy was given to 5 pts. At last follow-up 43 (70.5%) were disease free, 10 (16.4%) were alive with disease & no data was available for the rest.
Conclusion: Surgery and PORT is an effective combination for major salivary gland carcinoma with over 90% compliance and <20% recurrence. Newer therapy including chemotherapy & targeted therapy should be explored.

8550 POSTER

Clinical experience with Cetuximab and Paclitaxel combination in metastatic/recurrent squamous cell cancer carcinoma of the head and neck (SCCHN) - retrospective analysis of a single institution

I. Diaz de Corcuera[1], C. Serrano[1], J. Perez[1], I. Quispe[1], M. Arguis[2], E. Muñoz[1], S. Benavente[2], P. Martinez[1], M. Parera[1], M. del Campo[1].
[1]*Vall d'Hebron Hospital, Medical Oncology, Barcelona, Spain;* [2]*Vall d'Hebron Hospital, Radiotherapy, Barcelona, Spain*

Background: Results of a recent phase III randomized study with cetuximab and platin-5FU chemotherapy support its use in recurrent/metastatic SCCHN. However, many patients (pts) are not able to be treated with platin combinations. Paclitaxel (P) and Cetuximab (C) have shown an encouraging activity in a similar patients subset. We review the data of the patients treated with this schedule in our centre.
Material and Methods: From our database, we conducted a retrospective study of 20 patients with recurrent SCCHN who did not meet criteria for platin therapy and were treated with weekly P (80 mg/m^2) and C (initially 400 mg/m^2 followed by 250 mg/m^2) until progression or intolerable toxicity. We have collected data regarding previous treatments, response rate (RR), progression free survival (PFS), overall survival (OS) and toxicity.
Results: From January 2007 to November 2008, 20 patients were included (18 male, 2 female) with a median age of 63 (50−81). Oral cavity (35%) and oropharynx (25%) were the most frequent locations. Most of the pts (13/20) had been treated with previous chemotherapy combinations (range 1−3 lines). All pts were evaluable for response and toxicity. Overall RR was 45% (1CR, 8 PR) and 35% of the pts (7/10) had SD. Response in radiated areas were 35% (6/17). With a median follow up of 10 months the median PFS and OS were 6.5 and 7 months respectively. Main related toxicities (Gr 2/3) were acne-like rash (30%), asthenia (15%), anemia (10%) and mucositis (10%).
Conclusions: Our analysis supports the results of efficacy and safety of weekly paclitaxel-cetuximab combination in metastatic/recurrent SCCHN. Treatment is very well tolerated and could be considerated as an alternative to platin-based chemotherapy in unfit patients for this therapy.

8551 POSTER

Assessment of oxidative stress in tumors cells and histologically normal mucosa from head and neck squamous cell carcinoma patients

D. Dequanter[1], K. Zouaoui[2], V. Nuyens[2], A. Rousseau[2], D. Brohée[3], M. Van Haeverbeek[4], P.h. Lothaire[1]. [1]*CHU André Vésale, Surgery, Montigny le Tilleul, Belgium;* [2]*CHU André Vésale, Experimental Research, Montigny le Tilleul, Belgium;* [3]*CHU André Vésale, Oncology, Montigny le Tilleul, Belgium;* [4]*CHU André Vésale, Medecine, Montigny le Tilleul, Belgium*

Background: One of the cancers with strongest link to oxidative damage and oxidative stress is head and neck squamous cell carcinoma (HNSCC) since tobacco and alcohol are clearly defined as etiologic factors for these malignancies. Oxidative damage is the main mechanism mediating the clinical treatment effect of radiotherapy, the increased resistance to oxidative stress by many malignant cells is associated to treatment failure. Indeed, the response to radiation treatment varies from patient to patient. The purpose of this study was to compare the tissue levels of glutathione in HNSCC tumoral tissue (Tum) and corresponding adjacent histollogically cancer free mucosa (Muc) biopsies and to determine the potential variability in terms of radiosensibility.
Material and Methods: 27 newly diagnosed HNSCC patients were prospectively included in the study. All the patients were smokers. 27 tumoral specimens and an equal number of specimens from normal mucosa were examined. The ratio oxyded reduced glutathione is realised with the capillary electrophoresis kit Ceofix GSH/GSSG kit of Analis (Namur, Belgium). Two hundred microl of total blood, healthy and tumoral tissues were harvested on patient directly grind with 600 microl metaphosphoric acid 5% and centrifuged (within 3 hours). 100 microl of the supernatant was mixed with 400 microl of the kit diluent containing Naphthalene sulfonic acid as internal standard. Analysis is performed on a P/ACE 5000 series with a 37 cm and 75 micro m i.d. capillary maintained at 25°C. The separation was realized at 8 kV with a borate buffer pH8.2 containing SDS. The glutathione peaks were detected at 200 nm and integrated. The area of the oxyded glutathione peak is divided by the reduced one. Clinicopathological parameters were also analyzed as potential factors explicating the potential variability of oxidative stress status in HNSCC tumoral tissue.
Results: The ratio oxidized glutathione (GSSG)/reduced glutathione (GSH) determinated in tumoral tissue was higher in 12/27 of the cases comparing the ratio in adjacent normal tissue.
Conclusion: Pre therapeutic HNSCC tumoral tissue presented different GSH levels regarding adjacent cancer free mucosa. This difference is not related with clinicoanatomopathological parameters. GSH determination could have the potential to predict individual radiosensitivity of tumors of the head and neck area.

8552 POSTER

Gene hypermethylation in tumor tissue of oral squamous cell carcinoma patients: experience from Serbia

Z. Magic[1], G. Supic[1], R. Kozomara[2], M. Brankovic-Magic[3], N. Jovic[2].
[1]*Military Medical Academy, Institute for Medical Research, Belgrade, Serbia;* [2]*Military Medical Academy, Clinic of Maxillofacial Surgery, Belgrade, Serbia;* [3]*Institute for Oncology and Radiology of Serbia, Department of Experimental Oncology, Belgrade, Serbia*

Background: Oral squamous cell carcinoma (OSCC) is most frequently presenting as an aggressive and locally advanced disease with overall survival rate less than 40%. The mechanisms underlying the process of carcinogenesis and tumor aggressiveness act through an accumulation of genetic and epigenetic alterations that disrupt normal function of tumor suppressors and oncogenes. Epigenetic changes alter expression of genes without changes in DNA sequence. The most common epigenetic modification occurring in human tumors is DNA methylation and histone deacetylation. The aim of this study was to investigate the influence of gene hypemethylation on clinical course of disease of OSCC patients. Genes studied are known to be involved in various cellular processes such as cell cycle control (p16), apoptosis (Death associated protein kinase – DAPK), Wnt signaling (adenomatous polyposis coli – APC), cell-cycle adhesion (E-cadherin – E-cad) and DNA repair (O^6-Methylguanine-DNA-methyltranspherase – MGMT, Werner syndrome – WRN).
Materials and Methods: 77 OSCC patients with stage II (n = 18) and stage III (n = 59) patients were included. All underwent surgery as primary treatment and subsequently were treated with radiotherapy. DNAs for gene